AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

Bearish flow noted in AbbVie (ABBV) with 6,427 puts trading, or 1.5x expected. Most active are 4/11 weekly 210 puts and Mar-25 190 calls, with ...

Erste Group upgraded AbbVie (ABBV) to Buy from Hold.Light Up your Portfolio with Spark:Easily identify stocks' risks and opportunities.

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD ...

Instead of leading with a brand name and logo, DiBona said drugmakers should opt to create relevant content around raising awareness of certain diseases. They can also promote medications while ...

You can now play an even larger range of puzzles on our site, every weekday and now also every Saturday. Check out our brand new puzzles below, from Hangman to Add Up and even a Jigsaw. Of course ...

good evening. i'm abby phillip in new york. let's get right to what america is talking about. a debate over protests at the heart of it. should liberals be cheering on the demise of tesla as elon musk ...

alone. that's all for this hour. i'm michael steele inside with jen psaki, starts now. >> okay. i was. out last week. i sort of a. >> lot of thoughts. >> about all sorts. >> of things. >> i didn't ...